RU2005108667A - Производные n-биарилметиламиноциклоалканкарбоксамида - Google Patents
Производные n-биарилметиламиноциклоалканкарбоксамида Download PDFInfo
- Publication number
- RU2005108667A RU2005108667A RU2005108667/04A RU2005108667A RU2005108667A RU 2005108667 A RU2005108667 A RU 2005108667A RU 2005108667/04 A RU2005108667/04 A RU 2005108667/04A RU 2005108667 A RU2005108667 A RU 2005108667A RU 2005108667 A RU2005108667 A RU 2005108667A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- halogen
- hydrogen
- alkyl
- compound according
- Prior art date
Links
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
Claims (32)
1. Соединение формулы I и его фармацевтически приемлемые соли:
где Het представляет собой пиримидинил или пиридил, или их N-оксид;
R1 и R2 независимо выбирают из водорода и С1-4 алкила;
R3a и R3b независимо выбирают из водорода и С1-4 алкила, необязательно замещенного 1-5 атомами галогена;
R4a и R4b независимо выбирают из (1) водорода, (2) галогена и (3) С1-4 алкила, необязательно замещенного 1-4 группами, выбираемыми из галогена, ORa, OC(O)Ra, S(O)kRd, OS(O)2Rd и NR1R2 или
R4a и R4b вместе с атомом углерода, к которому они оба присоединены, образуют экзоциклический метилен, необязательно замещенный 1-2 группами, выбираемыми из C1-4 алкила, необязательно замещенного 1-5 атомами галогена, и С1-4 алкокси;
R5 выбирают из (1) С1-6 алкила, необязательно замещенного 1-5 группами, независимо выбираемыми из галогена, нитро, циано, ORa, SRa, CORa, SO2Rd, CO2Ra, OC(O)Ra, NRbRc, NRbC(O)Ra, NRbC(O)2Ra, C(O)NRbRc, С3-8 циклоалкила, (2) C3-8 циклоалкила, необязательно замещенного 1-5 группами, независимо выбираемыми из галогена, нитро, циано и фенила, (3) С3-6 алкинила, (4) С2-6 алкенила, необязательно замещенного гидроксиэтилом, (5) (СН2)k-арила, необязательно замещенного 1-3 группами, независимо выбираемыми из галогена, нитро, циано, ORa, SRa, C(O)2Ra, С1-4 алкила и С1-3 галогеналкила, где арил выбирают из фенила, 3,4-метилендиоксифенила и нафтила, (6) (СН2)k-гетероцикла, необязательно замещенного 1-3 группами, независимо выбираемыми из галогена, нитро, циано, ORa, SRa, С1-4 алкила и С1-3 галогеналкила, где указанный гетероцикл выбирают из (а) 5-членного гетероароматического цикла, имеющего гетероатом цикла, выбираемый из N, O и S и необязательно имеющий до 3 дополнительных атомов азота в цикле, где указанный цикл необязательно является бензо-конденсированным; (b) 6-членного гетероароматического цикла, содержащего от 1 до 3 атомов азота в цикле и их N-оксидов, где указанный цикл является необязательно бензо-конденсированным; и (с) 5- или 6-членного неароматического гетероциклического цикла, выбираемого из тетрагидрофуранила, 5-оксотетрагидрофуранила, 2-оксо-2Н-пиранила и 6-оксо-1,6-дигидропиридазинила, (7) C(O)2Ra, (8) C(O)NRbRc и (9) NRbCO2Ra;
R6a выбирают из (1) С1-8 алкила необязательно замещенного 1-5 группами, независимо выбираемыми из галогена, нитро, циано, CORa, CO2Ra, C(O)NRbRc, ORa, OC(O)Ra, SRa, SO2Rd, S(O)Rd, NRbRc, NRbC(O)Ra, NRbSO2Rd, NRbCO2Ra, (2) C3-8 циклоалкила, (3) С2-8 алкенила, необязательно замещенного CO2Ra, (4) галогена, (5) циано, (6) нитро, (7) NRbRc, (8) NRbC(O)Ra, (9) NRbCO2Ra, (10) NRbC(O)RbRc, (11) NRbC(O)NRbCO2Ra, (12) NRbSO2Rd, (13) CO2Ra, (14) CORa, (15) C(O)NRbRc, (16) C(O)NHORa, (17) C(=NORa)Ra, (18) C(=NORa)NRbRc, (19) ORa, (20) OC(O)kRa, (21) S(O)kRd, (22) SO2NRbRc и (23) необязательно замещенного гетероцикла, где гетероцикл выбирают из (а) 5-членного гетероароматического цикла, имеющего гетероатом цикла, выбираемый из N, O и S и необязательно имеющего до 3 дополнительных атомов азота в цикле, (b) 4,5-дигидрооксазолила, и (3) 4,5-дигидро-1,2,4-оксадиазолила, и где указанный заместитель является 1-3 группами, независимо выбираемыми из С1-4 алкила, необязательно замещенного 1-5 атомами галогена, ORa или OC(O)Ra,
R6b и R6с независимо выбирают из водорода и группы из R6a; при условии, что не более чем один из R6a, R6b и R6с является гетероциклом;
R7a и R7b независимо выбирают из водорода, галогена, циано, нитро, ORa, CO2Ra, C(O)NRbRc, SO2Rd, NRbRc, и С1-4 алкила, необязательно замещенного 1-5 атомами галогена;
Ra выбирают из (1) водорода, (2) С1-4 алкила, необязательно замещенного 1-5 атомами галогена, (3) фенила, необязательно замещенного 1-3 группами, независимо выбираемыми из галогена, циано, нитро, ОН, С1-4 алкилокси, С3-6 циклоалкила и С1-4 алкила, необязательно замещенного 1-5 атомами галогена, (4) С3-6 циклоалкила и (5) пиридила;
Rb и Rc независимо выбирают из (1) водорода, (2) С1-4 алкила, необязательно замещенного 1-5 группами, независимо выбираемыми из галогена, амино, моно-С1-4алкиламино, ди-С1-4алкиламино и SO2Rd, (3) (CH2)k-фенила, необязательно замещенного 1-3 группами, выбираемыми из галогена, циано, нитро, ОН, С1-4 алкилокси, С3-6 циклоалкила и С1-4 алкила, необязательно замещенного 1-5 атомами галогена и (4) С3-6 циклоалкила, или
Rb и Rc вместе с атомом азота, к которому они присоединены, образуют 4-, 5- или 6-членный цикл, необязательно содержащий дополнительный гетероатом, выбираемый из N, O и S; или
Rb и Rc вместе с атомом азота, к которому они присоединены, образуют циклический имид;
Rd выбирают из (1) С1-4 алкила, необязательно замещенного 1-5 атомами галогена, (2) С1-4 алкилокси, (3) фенила, необязательно замещенного 1-3 группами, выбираемыми из галогена, циано, нитро, ОН, С1-4 алкилокси, С3-6 циклоалкила и С1-4 алкила, необязательно замещенного 1-5 атомами галогена;
k составляет 0, 1 или 2; и
m составляет 0, 1, 2 или 3.
2. Соединение по п.1, где R5 представляет собой С1-6 алкил, необязательно замещенный 1-5 группами, независимо выбираемыми из галогена, нитро, циано, ORa, SRa, CORa, SO2Rd, CO2Ra, OC(O)Ra, NRbRc, NRbC(O)Ra, C(O)NRbRc и С3-8 циклоалкила, 1,2,5-тиадиазолила, изоксазолила, изотиазолила или пиримидинила.
3. Соединение по п.1, где R5 представляет собой С1-3 алкил, необязательно замещенный 1-5 группами атомов галогена, где указанным галогеном является хлор или фтор.
4. Соединение по п.1, где R5 выбирают из дифторметила, дихлорметила, хлордифторметила, трифторметила, 1,1-дихлорэтила и 2,2,2-трифторэтила.
5. Соединение по п.1, где R5 является пиримидинилом.
6. Соединение по п.1, где R5 является 1,2,5-тиадиазолилом, изоксазолилом или изотиазолилом.
7. Соединение по п.1, где R6а является ORa, CO2Ra или тетразолилом, необязательно замещенным С1-4алкилом.
8. Соединение по п.1, где R6а является ORa, CO2Ra или тетразолилом, необязательно замещенным С1-4алкилом, R6b является водородом или галогеном, и R6с является водородом или галогеном.
9. Соединение по п.1, где R6а является метоксикарбонилом, этоксикарбонилом, С1-4алкокси, необязательно замещенным 1-5 атомами галогена, или 2-метил-2Н-тетразол-5-илом, R6b является фтором или хлором и R6с является водородом, хлором или фтором.
10. Соединение по п.1, где Het представляет собой 2,5-пиридинедиил и R7а и R7b являются независимо водородом или галогеном.
11. Соединение по п.10, где один из R7а и R7b является водородом и другой является фтором или хлором.
12. Соединение по п.1, где m составляет 0 или 1.
14. Соединение по п.13, где m равно 0 или 1, и один из R3а и R3b является водородом и другой является водородом или С1-3алкилом.
15. Соединение по п.13, где Х является углеродом, R7а является водородом или хлором или фтором и R7b является водородом.
16. Соединение по п.13, где Х является азотом и R7а и R7b каждый являются водородом.
18. Соединение по п.17, где R3a является водородом и R6b и R7a являются каждый независимо хлором или фтором.
19. Соединение по п.17, где R3a является водородом, R6b и R7a каждый являются независимо хлором или фтором, R5 выбирают из изоксазолила, тиазолила, 1,2,5-тиадиазолила, 5-пиримидинила и С1-2алкила, замещенного 1-3 атомами галогена, выбираемыми из хлора и фтора, и R6a является ORa, CO2Ra или 2-метил-5-тетразолилом.
21. Соединение по п.20, где R6b является водородом, и R6c и R7a являются независимо водородом или галогеном.
22. Соединение по п.20, где R5 выбирают из изоксазолила, изотиазолила, 1,2,5-тиадиазолила, 5-пиримидинила и С1-2алкила, замещенного 1-5 атомами галогена.
23. Соединение по п.21, где R5 выбирают из изоксазолила, изотиазолила, 1,2,5-тиадиазолила, 5-пиримидинила и С1-2алкила, замещенного 1-5 атомами галогена.
24. Соединение по п.20, где R6a выбирают из CO2C1-4алкила, С1-4алкокси, необязательно замещенного 1-5 атомами галогена и 2-метил-5-тетразолила.
25. Соединение по п.23, где R6a выбирают из CO2C1-4алкила, С1-4 алкокси, необязательно замещенного 1-5 атомами галогена и 2-метил-5-тетразолила.
26. Фармацевтическая композиция, включающая терапевтически эффективное количество соединения по п.1 и фармацевтически приемлемые носители.
27. Способ лечения или предотвращения боли и воспаления, включающий стадию введения субъекту, нуждающемуся в таком лечении или предотвращении, эффективного количества соединения по п.1 или его фармацевтически приемлемой соли.
28. Способ лечения остеоартрита, повторяющейся боли при движении, зубной боли, раковой боли, миофасциальной боли, боли при повреждении мышц, боли при фибромиалгии, послеоперационной боли, включающий стадию введения субъекту, нуждающемуся в таком лечении, эффективного количества соединения по п.1 или его фармацевтически приемлемой соли.
29. Способ лечения или предотвращения воспалительной боли, вызываемой хроническими обструктивными заболеваниями легких, астмой, воспалительными заболеваниями кишечника, ринитом, панкреатитом, циститом (интерстициальным циститом), увеитом, воспалительными заболеваниями кожи, ревматоидным артритом, отеком, возникающим в результате травмы, ассоциированной с ожогами, растяжениями или переломами, постхирургическими вмешательствами, остеоартритом, ревматическими заболеваниями, тено-синовиитом или подагрой, включающий стадию введения субъекту, нуждающемуся в таком лечении или предотвращении, эффективного количества соединения по п.1 или его фармацевтически приемлемой соли.
30. Способ лечения или предотвращения боли, связанной со стенокардией, менструацией или раком, включающий стадию введения субъекту, нуждающемуся в таком лечении или предотвращении, эффективного количества соединения по п.1 или его фармацевтически приемлемой соли.
31. Способ лечения диабетической васкулопатии, посткапиллярной устойчивости, диабетических симптомов, связанных с инсулитом, псориаза, экземы, спазма желудочно-кишечного тракта или матки, болезни Крона, язвенного колита или панкреатита, включающий стадию введения субъекту, нуждающемуся в таком лечении эффективного количества соединения по п.1 или его фармацевтически приемлемой соли.
32. Способ лечения или предотвращения боли, вызываемой пневмокониозом, включая алюминоз, антракоз, асбестоз, халикоз, птилоз, сидероз, силикоз, табакоз, биссиноз, респираторным дистресс-синдромом взрослых, бронхитом, аллергическим ринитом, вазомоторным ринитом, болезнями печени, рассеянным склерозом, атеросклерозом, болезнью Альцгеймера, септическим шоком, отеком мозга, головной болью, мигренью, закрытой травмой головы, синдромом раздраженного кишечника или нефритом, включающий стадию введения субъекту, нуждающемуся в таком лечении или предотвращении боли, эффективного количества соединения по п.1 или его фармацевтически приемлемой соли.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40674202P | 2002-08-29 | 2002-08-29 | |
US60/406,742 | 2002-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2005108667A true RU2005108667A (ru) | 2005-08-27 |
Family
ID=31978351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005108667/04A RU2005108667A (ru) | 2002-08-29 | 2003-08-25 | Производные n-биарилметиламиноциклоалканкарбоксамида |
Country Status (15)
Country | Link |
---|---|
US (1) | US7163951B2 (ru) |
EP (1) | EP1545538A2 (ru) |
JP (1) | JP2005537323A (ru) |
KR (1) | KR20050033660A (ru) |
CN (1) | CN1678320A (ru) |
AU (1) | AU2003265674B2 (ru) |
BR (1) | BR0313239A (ru) |
CA (1) | CA2495914A1 (ru) |
IL (1) | IL166426A0 (ru) |
MX (1) | MXPA05002245A (ru) |
NO (1) | NO20051539L (ru) |
PL (1) | PL374529A1 (ru) |
RU (1) | RU2005108667A (ru) |
WO (1) | WO2004019868A2 (ru) |
ZA (1) | ZA200500471B (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1654232A4 (en) * | 2003-08-07 | 2008-11-12 | Merck & Co Inc | N- (BIARYLMETHYL) AMINOCYCLOPROPANECARBOXAMIDES WITH SULFONYL SUBSTITUTION |
EP1720856B1 (en) | 2004-02-11 | 2013-08-14 | GlaxoSmithKline LLC | Hiv integrase inhibitors |
WO2005085198A2 (en) * | 2004-03-02 | 2005-09-15 | Merck & Co., Inc. | Amino cyclopropane carboxamide derivatives as bradykinin antagonists |
US7429604B2 (en) * | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
WO2006071775A2 (en) * | 2004-12-29 | 2006-07-06 | Elan Pharmaceuticals, Inc. | Novel compounds useful for bradykinin b1 receptor antagonism |
CA2610059A1 (en) | 2005-06-03 | 2006-12-14 | Merck & Co., Inc. | 1-hydroxycycloalkanecarboxamide derivatives as bradykinin antagonists |
EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
WO2009027450A1 (de) | 2007-08-29 | 2009-03-05 | Boehringer Ingelheim International Gmbh | Neue bradykinin b1-antagonisten |
WO2009132453A1 (en) * | 2008-04-28 | 2009-11-05 | Neuromed Pharmaceuticals Ltd. | Cyclylamine derivatives as calcium channel blockers |
WO2010031577A1 (en) * | 2008-09-18 | 2010-03-25 | Jerini Ag | Use of bradykinin b1 receptor antagonists in intestinal fibrosis treatment |
CN102414177B (zh) * | 2009-02-26 | 2014-07-02 | 贝林格尔.英格海姆国际有限公司 | 作为缓激肽b1拮抗剂的化合物 |
WO2010097373A1 (de) * | 2009-02-26 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Verbindungen als bradykinin b1 antagonisten |
CA2764296A1 (en) * | 2009-06-02 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Derivatives of 6,7-dihydro-5h-imidazo[1,2-.alpha.]imidazole-3-carboxylic acid amides |
KR101628132B1 (ko) * | 2010-01-25 | 2016-06-08 | 주식회사 바이오씨에스 | 신규한 바이아릴아미드 유도체 및 이를 유효성분으로 함유하는 조성물 |
CA2790952C (en) | 2010-02-23 | 2017-07-04 | Boehringer Ingelheim International Gmbh | Compounds as bradykinin b1 antagonists |
US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
HUP1000598A2 (en) * | 2010-11-05 | 2012-09-28 | Richter Gedeon Nyrt | Indole derivatives |
US8912221B2 (en) * | 2010-12-27 | 2014-12-16 | Hoffmann-La Roche Inc. | Biaryl amide derivatives |
US8592426B2 (en) * | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
NO2686520T3 (ru) * | 2011-06-06 | 2018-03-17 | ||
US11857543B2 (en) | 2013-06-13 | 2024-01-02 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
JP2018502882A (ja) | 2015-01-23 | 2018-02-01 | アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. | 2−(5−(3−フルオロフェニル)−3−ヒドロキシピコリンアミド)酢酸の固体形態、その組成物及び使用 |
MX2017012460A (es) | 2015-04-01 | 2018-01-30 | Akebia Therapeutics Inc | Composiciones y metodos para el tratamiento de la anemia. |
TWI822776B (zh) | 2018-05-09 | 2023-11-21 | 美商阿克比治療有限公司 | 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023265A (en) * | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
IL99372A0 (en) | 1990-09-10 | 1992-08-18 | Ciba Geigy Ag | Azacyclic compounds |
AR038377A1 (es) | 2002-02-08 | 2005-01-12 | Merck & Co Inc | Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo) |
ATE316954T1 (de) | 2002-02-08 | 2006-02-15 | Merck & Co Inc | N-biphenylmethylaminocycloalkancarboxamid- derivative |
-
2003
- 2003-08-25 US US10/523,911 patent/US7163951B2/en not_active Expired - Fee Related
- 2003-08-25 MX MXPA05002245A patent/MXPA05002245A/es not_active Application Discontinuation
- 2003-08-25 KR KR1020057003550A patent/KR20050033660A/ko not_active Application Discontinuation
- 2003-08-25 RU RU2005108667/04A patent/RU2005108667A/ru not_active Application Discontinuation
- 2003-08-25 PL PL03374529A patent/PL374529A1/xx not_active Application Discontinuation
- 2003-08-25 AU AU2003265674A patent/AU2003265674B2/en not_active Ceased
- 2003-08-25 CA CA002495914A patent/CA2495914A1/en not_active Abandoned
- 2003-08-25 WO PCT/US2003/026628 patent/WO2004019868A2/en active Application Filing
- 2003-08-25 EP EP03791763A patent/EP1545538A2/en not_active Withdrawn
- 2003-08-25 CN CNA03820293XA patent/CN1678320A/zh active Pending
- 2003-08-25 BR BR0313239-0A patent/BR0313239A/pt not_active Application Discontinuation
- 2003-08-25 IL IL16642603A patent/IL166426A0/xx unknown
- 2003-08-25 JP JP2004532994A patent/JP2005537323A/ja active Pending
-
2005
- 2005-01-18 ZA ZA2005/00471A patent/ZA200500471B/en unknown
- 2005-03-23 NO NO20051539A patent/NO20051539L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CA2495914A1 (en) | 2004-03-11 |
AU2003265674B2 (en) | 2008-12-11 |
CN1678320A (zh) | 2005-10-05 |
US20050288305A1 (en) | 2005-12-29 |
WO2004019868A3 (en) | 2004-04-29 |
IL166426A0 (en) | 2006-01-15 |
JP2005537323A (ja) | 2005-12-08 |
US7163951B2 (en) | 2007-01-16 |
BR0313239A (pt) | 2005-06-14 |
EP1545538A2 (en) | 2005-06-29 |
WO2004019868A2 (en) | 2004-03-11 |
AU2003265674A1 (en) | 2004-03-19 |
MXPA05002245A (es) | 2005-06-08 |
ZA200500471B (en) | 2006-07-26 |
PL374529A1 (en) | 2005-10-31 |
KR20050033660A (ko) | 2005-04-12 |
NO20051539L (no) | 2005-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005108667A (ru) | Производные n-биарилметиламиноциклоалканкарбоксамида | |
EP3877376B1 (en) | Pyridazinone compounds and uses thereof | |
JP2005517006A5 (ru) | ||
ATE293109T1 (de) | Nikotinsäureamid-derivate und ihre mimetika als inhibitoren von pde4-isozyms | |
JP2005537323A5 (ru) | ||
HRP20181076T1 (hr) | Pirazolski derivati kao modulatori kalcijevih kanala aktiviranih oslobađanjem kalcija | |
CA2648914C (en) | Pyridyloxadiazole substituted compounds and compositions | |
JP2007519735A5 (ru) | ||
RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
CA2553160A1 (en) | 2-heteroaryl-substituted benzimidazole derivative | |
AR067850A1 (es) | Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit | |
AR057848A1 (es) | Diarilureas para el tratamiento de la hipertension pulmonar | |
RU2009116670A (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
JP2008504304A5 (ru) | ||
CA2644425A1 (en) | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors | |
RU2004135066A (ru) | Ингибиторы деацетилазы гистонов | |
HUP0303876A2 (hu) | 2 Típusú diabétesz kezelésére alkalmas gyógyszerkészítmény előállítása dipeptidil-peptidáz IV inhibitor hatású piperidin vagy tiazolidinszármazékok alkalmazásával | |
MX2014015350A (es) | Compuestos de triazolona como inhibidores de mpegs-1. | |
CA2684105A1 (en) | Pyridine derivatives | |
JP2009525285A5 (ru) | ||
SK10197A3 (en) | Aromatic amino ethers, preparation methods thereof and pharmaceutical agents containing them | |
CA2409715A1 (en) | .beta.-carboline derivatives useful as inhibitors of phosphodiesterase | |
RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
JP2005516979A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070620 |